Noticias de NVCR_US

Noticias del mercado

Últimas noticias sobre NVCR_US — 55 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: NVCR_US ✕ 55 resultados
13/02/2026 NVCR_US — Blockonomi
NovoCure (NVCR) Stock Surges on Pancreatic Cancer Treatment Approval
12/02/2026 NVCR_US — Stocktwits
NVCR Rallies On FDA Approval For Cancer Treatment Device, Analyst Still Sees 275% Potential Upside
12/02/2026 NVCR_US — parameter.io ES ← EN
Las acciones de NovoCure (NVCR) aumentan un 29% con la aprobación de la FDA para el tratamiento del cáncer de páncreas
12/02/2026 NVCR_US — simplywall.st
NovoCure Limited's (NASDAQ:NVCR) 26% Dip In Price Shows Sentiment Is Matching Revenues
12/02/2026 NVCR_US — FinancialContent
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
12/02/2026 NVCR_US — Forbes
What’s Happening With NovoCure Stock?
12/02/2026 NVCR_US — Seeking Alpha
Novocure shares surge after FDA approves Optune Pax for pancreatic cancer (NVCR:NASDAQ)
12/02/2026 NVCR_US — Seeking Alpha
NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching
12/02/2026 NVCR_US — StocksToTrade
Novocure’s Optune Pax Receives FDA Nod, Accelerates Cancer Treatment Landscape
12/02/2026 NVCR_US — timothysykes.com
Novocure Achieves Major Milestone with FDA Approval for Innovative Cancer Treatment
12/02/2026 NVCR_US — Stocktwits
Why NVCR Stock Is Surging Nearly 30% In Overnight Trading
11/02/2026 NVCR_US — WSJ
Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar
07/02/2026 NVCR_US — MSN ES ← EN
NovoCure proyecta ingresos mensuales de $13 millones debido a que Medicare revoca los privilegios de facturación
06/02/2026 NVCR_US — MSN ES ← EN
NovoCure proyecta ingresos mensuales de $13 millones debido a que Medicare revoca los privilegios de facturación
06/02/2026 NVCR_US — Seeking Alpha
Why NovoCure Is No Longer A Clear Sell At These Lows (NASDAQ:NVCR)

Página 3 de 3

keyboard_arrow_up